Biotechnology Ireland-based biotech Prothena saw its shares close up 6.1% at $11.95, after it announced that, based on positive signals of efficacy consistent with disease modification in the PASADENA study, Swiss pharma giant Roche and Prothena plan to advance prasinezumab into a Phase IIb study in patients with early Parkinson’s disease. 22 October 2020